BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Total Current Assets
All assets expected to be converted to cash or used up within one year.
BioAge Labs, Inc.NASDAQ: BIOA
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets rises 20.6% from a year ago
Total current assets stood at $391.86M at the end of Q1 FY2026, up 20.6% from a year earlier and up 36.6% from the prior quarter. Over 3 fiscal years it compounded at +117.1% a year.
Context
- Total current assets amounted to 98.5% of total assets at the end of Q1 FY2026, up 4.1 pp from a year earlier.
- Total current assets increased in 1 of the last 3 fiscal years.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +20.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 286.79M USD
- Year-over-year change
- -19.7%
- 3-year CAGR
- +117.1%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 286.79M | -19.7% |
| FY2024 | 2024-12-31 | 357.1M | +1311.1% |
| FY2023 | 2023-12-31 | 25.31M | -9.7% |
| FY2022 | 2022-12-31 | 28.03M | — |
Total Current Assets vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so total current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +20.6% is the 2nd highest of 9, against a peer median of -15.0%.
- Total current assets amounts to 98.5% of total assets for BIOA, versus a peer median of 66.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$529.47M CAD | +79.7% | -11.8% | 47.3% | |
| Mar 2026 | CA$398.48M CAD | -16.2% | -6.0% | 66.1% | |
BIOABioAge Labs, Inc. | Mar 2026 | $391.86M USD | +20.6% | +117.1% | 98.5% |
| Mar 2026 | $273.29M USD | -6.3% | -21.3% | 69.0% | |
| Mar 2026 | $263.2M USD | -39.3% | -22.2% | 98.5% | |
| Mar 2026 | $128.07M USD | -43.0% | -22.8% | 85.8% | |
| Mar 2026 | $122.32M USD | -9.1% | +8.5% | 82.6% | |
| Dec 2025 | $82.29M USD | — | — | 35.4% | |
| Mar 2026 | $63.6M USD | -13.7% | -24.0% | 57.5% | |
| Mar 2026 | $31.67M USD | -20.3% | -17.4% | 32.1% | |
| Peer median (excluding BIOA) | — | -15.0% | -19.3% | 66.1% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.